En-tête de navigationNavigation principaleSuiviFiche


Unité de recherche
INNOSUISSE
Numéro de projet
18525.1 PFLS-LS
Titre du projet
Assessment of the efficacy of treatment of patients with sickle cell disease with memantine (phase IIa-b trial|MemSID) using novel analytical techniques
Titre du projet anglais
Assessment of the efficacy of treatment of patients with sickle cell disease with memantine (phase IIa-b trial|MemSID) using novel analytical techniques

Textes relatifs à ce projet

 AllemandFrançaisItalienAnglais
Description succincte
Anzeigen
-
-
Anzeigen
Résumé des résultats (Abstract)
Anzeigen
-
-
Anzeigen

Textes saisis


CatégorieTexte
Description succincte
(Allemand)
Effizienzbestimmung der Behandlung von Sichelzellanämiepatienten mit dem Wirkstoff|Memantin (Phase IIa-b trial MemSID) mittels neueartiger Analysemethoden
Description succincte
(Anglais)
Assessment of the efficacy of treatment of patients with sickle cell disease with memantine (phase IIa-b trial|MemSID) using novel analytical techniques
Résumé des résultats (Abstract)
(Allemand)
Memantine, the NMDA receptor anatagonist is for the first time applied for treatment of patients with sickle cell|disease. The existing clinical lab test are insufficient to assess the effect of the drug on properties of the|circulating red cells. We suggest a battery of tests to evaluate red cell adherence, deformability, redox state,|calcium levels, volume and ion content using apporaches including novel microfluidic devices produced by our|industrial partners.
Résumé des résultats (Abstract)
(Anglais)
Memantine, the NMDA receptor anatagonist is for the first time applied for treatment of patients with sickle cell|disease. The existing clinical lab test are insufficient to assess the effect of the drug on properties of the|circulating red cells. We suggest a battery of tests to evaluate red cell adherence, deformability, redox state,|calcium levels, volume and ion content using apporaches including novel microfluidic devices produced by our|industrial partners.